Erratum: Pioglitazone, a PPARg Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1 (Cancer Prev Res (2012) 5 (1183–1194) DOI: 10.1158/1940-6207.CAPR-12-0201);Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: Evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1

Cancer Prevention Research

Volumn 5, Issue 10, 2012, Pages 1183-1194

  Subbaramaiah, Kotha ^a   Howe, Louise R ^b   Zhou, Xi Kathy ^b   Yang, Peiying ^d   Hudis, Clifford A ^c   Kopelovich, Levy ^e   Dannenberg, Andrew J ^a  

^a Weill Cornel Medical College   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; AROMATASE; BRCA1 PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; PIOGLITAZONE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR SNAIL;

ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION;

EID: 84867377906     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-22-0204     Document Type: Erratum

References (38)

1. Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 2009;150:2537-42.
2. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
3. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83. (Pubitemid 41196955)
4. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006;13:279-92. (Pubitemid 43886659)
5. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012;23:83-9.
6. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 2006;81:55-70. (Pubitemid 44403171)
7. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008;283:3433-44.
8. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
9. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, et al. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006;66:5504-11. (Pubitemid 43844979)
10. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-7. (Pubitemid 34158777)
11. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35. (Pubitemid 29251310)
12. Subbaramaiah K, HoweLR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with infl ammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4:329-46.
13. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
14. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, et al. Nonsteroidal anti-in flammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:680-7. (Pubitemid 351469220)
15. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-9.
16. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007;28:551-8. (Pubitemid 350101420)
17. Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, et al. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. Endocrinology 2005;146:85-92. (Pubitemid 40051727)
18. Rubin GL, Duong JH, Clyne CD, Speed CJ, Murata Y, Gong C, et al. Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology 2002;143:2863-71. (Pubitemid 34809856)
19. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-8. (Pubitemid 30183431)
20. Safi R, Kovacic A, Gaillard S, Murata Y, Simpson ER, McDonnell DP, et al. Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy. Cancer Res 2005;65:11762-70. (Pubitemid 41821738)
21. Yanase T, Mu YM, Nishi Y, Goto K, Nomura M, Okabe T, et al. Regulation of aromatase by nuclear receptors. J Steroid Biochem Mol Biol 2001;79:187-92. (Pubitemid 34158794)
22. Clyne CD, Speed CJ, Zhou J, Simpson ER. Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem 2002;277:20591-7. (Pubitemid 34967360)
23. Hazra S, Batra RK, TaiHH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-20. (Pubitemid 47010924)
24. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001;276:12440-8.
25. Pignatelli M, Cocca C, Santos A, Perez-Castillo A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene 2003;22:5446-50. (Pubitemid 37072199)
26. Ghosh S, Lu Y, Katz A, Hu Y, Li R. Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. Am J Physiol Endocrinol Metab 2007;292:E246-52. (Pubitemid 46052947)
27. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8. (Pubitemid 43256356)
28. Lu M, Chen D, Lin Z, Reierstad S, Trauernicht AM, Boyer TG, et al. BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab 2006;91:4514-9. (Pubitemid 44833433)
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
30. Miyaki A, Yang P, Tai HH, Subbaramaiah K, Dannenberg AJ. Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. Am J Physiol Gastrointest Liver Physiol 2009;297:G559-66.
31. Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006;66:6649-56. (Pubitemid 44085621)
32. Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 2002;16:1861-8. (Pubitemid 35462604)
33. Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004;279:22057-65. (Pubitemid 38679397)
34. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996;85:403-14. (Pubitemid 26160711)
35. Chand AL, Simpson ER, Clyne CD. Aromatase expression is increased in BRCA1 mutation carriers. BMC Cancer 2009;9:148.
36. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol 2003;15:345-50. (Pubitemid 36638654)
37. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62.
38. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477:477-81.